24/7 Customer Support

Press Release

Neurostimulation Device Market Size Worth US$ 17,367 Mn by 2030 | CAGR: 9.7%

11 May 2022

The study published by Astute Analytica foresees a tremendous growth in revenue of the Global Neurostimulation Device Market from US$ 7,622.7 Mn in 2021 to US$ 17,367 Mn by 2030, registering a CAGR of 9.7% over the forecast period. In terms of volume, the market is recording a CAGR of 8.3% during 2022-2030. Neurostimulation involves the purposeful modulation of nervous system's activity using invasive (e.g., microelectrodes) or non-invasive means (e.g., transcranial magnetic). Neurostimulation devices treat the nervous system directly with implantable or wearable devices that rebalance neural circuitry with pulses of electrical currents. Further, Neurostimulation devices can improve the quality of life of those who are severely paralyzed or suffering from profound losses to various sense organs, as well as for permanent reduction of severe, chronic pain which otherwise requires high-dose opioid therapy.

The growing impetus of the market is attributed to factors such as the increasing incidence of neurological disorders and rising investment in neurological R&D. Neurological disorders are diseases of the central and peripheral nervous system. In other words, the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscles. These disorders include epilepsy, Alzheimer’s disease, and other dementias, cerebrovascular diseases including stroke, migraine, and other headache disorders, multiple sclerosis, Parkinson's disease, neuroinfectious, brain tumors, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition. Neurological disorders pose a large burden on worldwide health. Hundreds of millions of people worldwide are affected by neurological disorders. According to WHO (World Health Organization), more than 6 million people die because of stroke each year; over 80% of these deaths take place in low- and middle-income countries. More than 50 million people have epilepsy worldwide. It is estimated that there are globally 47.5 million people with dementia with 7.7 million new cases every year - Alzheimer's disease is the most common cause of dementia and may contribute to 60–70% of cases. The prevalence of migraine is more than 10% worldwide. With awareness of the massive burden associated with neurological disorders came the recognition that neurological services and devices were disproportionately scarce, especially in low-income and developing countries. This led to rising investments by various governments for neurological R&D. Furthermore, the adoption of emerging technologies, such as silicon micro-fabrication and wireless energy transfer is creating opportunities for market expansion. However, the high cost of neurostimulation procedures and equipment is restraining the overall market growth. 

Segmental Analysis

The segmentations considered to analyze the Global Neurostimulation Device Market are based on device type, applications, end-users, and region. In terms of device type, implantable devices hold the highest share in the market in 2021. Further, in terms of application, the pain management segment dominates the neurostimulation devices market in 2021. Hospital/clinics are the highest end-users in the market in 2021. Moreover, it is estimated that North America is the highest shareholder region in the Global Neurostimulation Device Market in 2021.

Regional Analysis:

  • North America dominates the Global Neurostimulation Device Market in 2021. The US is the highest shareholder country in the region in 2021. According to the Global Burden of Disease study - stroke, dementias, and migraine cause the most disability among neurological disorders in the United States. Pain management application holds the highest share in the neurostimulation market of North America in 2021.
  • Europe holds the second-highest share in the Global Neurostimulation Device Market in 2021. Poland registers the highest CAGR over the projection period 2022-2030. The population in Europe is older than that of the global population, suggesting that it might be particularly vulnerable to an increasing burden of age-related neurological disorders. Further, based on device type, implantable devices hold the highest market share in 2021.
  • The Asia Pacific region records the highest CAGR over the projection period owing to rising cases of depression and dementia in South Asian countries like Japan, South Korea, and China. Furthermore, rising disposable income in APAC countries has increased the healthcare expenditure of individuals, which again is expected to propel market growth over the forecast period. China is the highest shareholder country in the region and India is projected to grow at the highest growth rate over the forecast period. 
  • Saudi Arabia is the highest shareholder country in the Middle East & Africa neurostimulation market in 2021. This is due to the rising burden of neurological disorders and growing traumatic brain injuries in MEA. Based on device type, implantable devices hold the highest market share in 2021. Further, based on end-users, the hospitals/clinics segment holds the highest share in the MEA market. 
  • Brazil is the highest shareholder country in the South America, neurostimulation market in 2021 and further registers the highest CAGR over the forecast period. In terms of application, the pain management segment holds the highest share in the market in 2021. 

Competitive Dashboard

The key players in the Global Neurostimulation Device Market are Medtronic plc, Cochlear Ltd., Boston Scientific Corporation, and Abbott Laboratories, Inc. among others.

Strategies adopted by key market players:

  • In January 2021, Abbott launched NeuroSpher myPath, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy. 
  • In June 2021, Merck collaborated with neuroloop GmbH – a B. Braun subsidiary. The collaboration seeks to develop a neurostimulator device that can complement the existing drug therapies for patients with chronic inflammatory diseases.
  • In June 2021, Cochlear proposed a new multimodal approach- Electro-Haptic Stimulation that has shown improved speech-in-noise performance and sound localization in Cochlear implant users.
  • In December 2020, Boston Scientific Corporation announced the approval of the WaveWriter AlphaTM portfolio of Spinal Cord Stimulator (SCS) Systems by the US Food and Drug Administration (FDA). The portfolio includes four MRI conditional Bluetooth-enabled implantable pulse generators (IPGs), which provide increased customization based on patient preferences, including rechargeable and non-rechargeable alternatives, as well as access to waveforms that can cover different pain locations.

Segmentation Overview

The following are the various segments of the Global Neurostimulation Device Market:

By Device Type segment of the Global Neurostimulation Device Market is sub-segmented into:

  • Implantable Device
    • Cochlear Implants (CI)
    • Sacral Nerve Stimulation (SNS)
    • Gastric Electric Stimulation (GES)
    • Deep Brain Stimulation (DBS)
    • Vagus Nerve Stimulation (VNS)
    • Spinal Cord Stimulation (SCS)
  • External Device
    • Transcranial Magnetic Stimulation (TMS)
    • Transcutaneous Electrical Nerve Stimulation (TENS)

By Application segment of the Global Neurostimulation Device Market is sub-segmented into:

  • Pain Management
  • Hearing Loss
  • Urinary Incontinence
  • Parkinson's Disease
  • Epilepsy
  • Gastroparesis 
  • Depression
  • Others

By End User segment of the Global Neurostimulation Device Market is sub-segmented into:

  • Hospitals/Clinics
  • Cognitive Care Centres
  • Research Institutes
  • Others

By Region segment of the Global Neurostimulation Device Market is sub-segmented into:

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
    • Eastern Europe
    • Poland 
    • Russia
    • Rest of Eastern Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia & New Zealand
    • Rest of APAC
  • Middle East & Africa (MEA)
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of MEA
  • South America
    • Argentina
    • Brazil
    • Rest of South America

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:
https://www.astuteanalytica.com/request-sample/neurostimulation-device-market